New standards of care and novel treatment options for several forms of lymphoma unveiled
December 4, 2010 by admin · Leave a Comment
(ORLANDO, December 5, 2010) The next generation of drug therapies and enhanced treatment approaches for various forms of lymphoma are evolving as researchers continue to better understand how these cancers progress. Research will be presented today at the 52nd Annual Meeting of the American Society of Hematology introducing promising new options for the standard treatment of advanced asymptomatic follicular lymphoma, mantle cell lymphoma, and early, unfavorable (referring to patients with clinical stage I or II disease and one or more risk factors) Hodgkin disease. Other research highlights the efficacy of an innovative investigational agent that has the potential to become a new treatment option for patients with relapsed or refractory Hodgkin disease, which currently has no available treatment options.
New lymphoma therapy may be more effective with fewer side effects
November 2, 2010 by admin · Leave a Comment
Weill Cornell researchers report on targeted therapy to repress protein mutations in diffuse large B-cell lymphomas
NEW YORK (Nov. 3, 2010) — Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin’s lymphoma that accounts for approximately 40 percent of lymphomas among adults. If left untreated, it is fatal. The existing treatments have a cure rate that is slightly over 50 percent but destroy healthy cells along with the cancer cells.
A discovery could be important for the therapy of lymphoma and leukemia
October 31, 2010 by admin · Leave a Comment
The IRCM’s Dr. Javier M. Di Noia identifies a mechanism regulating activation-induced deaminase
A recent scientific discovery made by researchers at the Institut de recherches cliniques de Montréal (IRCM) led by Dr. Javier Marcelo Di Noia, Director of the Mechanisms and Genetic Diversity research unit, was published online today by The Journal of Experimental Medicine. The team identified a mechanism regulating activation-induced deaminase (AID), which could be important for the therapy of some types of lymphoma and leukemia.
New potential drug combination for most common form of non-Hodgkin’s lymphoma
October 31, 2010 by admin · Leave a Comment
Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma. Although 60% of patients can be cured with a currently available combination therapy, this leaves a substantial number of patients without a cure. However, a team of researchers, led by Ari Melnick, at Weill Cornell Medical College, New York, has now identified a potential new combinatorial therapy for DLBCL. Specifically, the team found that combining an inhibitor of the protein BCL6 with either an inhibitor of HDAC proteins or an inhibitor of the Hsp90 protein enhanced killing of primary human DLBCL cells in vitro relative to the use of the BCL6 inhibitor alone. Both drug combinations also potently suppressed the growth of established human DLBCL xenografts in mice or even eradicated the tumors completely. These data provide a rational basis for designing combination therapy clinical trials in patients with DLBCL. Read more
Study makes exciting progress in elucidating the mechanisms of bortezomib in lymphoma
July 11, 2010 by admin · Leave a Comment
Findings by the John Theurer Cancer Center may lead to more targeted clinical trials and therapies
HACKENSACK, N.J. (July 12, 2010) A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE®), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. The study also provides preliminary evidence for which patients might benefit most from bortezomib. Additionally, researchers demonstrate that biomarkers the genes and proteins that indicate biological processes might help guide the selection of patients for specific clinical trials and speed-up the development of targeted cancer drugs. The study, which is now published online, will also appear in the July issue of Leukemia & Lymphoma.
How to overcome resistance to 1 group of breast cancer drugs
June 6, 2010 by admin · Leave a Comment
Contact: Karen Honey
press_releases@the-jci.org
734-546-5242
Journal of Clinical Investigation
A team of researchers, led by Carlos Arteaga, at Vanderbilt University Medical Center, Nashville, has identified a mechanism by which human breast cancer cells can develop resistance to one group of drugs used to treat breast cancer, suggesting new approaches to treating the disease.
‘Scout scans’ map the way in non-Hodgkin’s lymphoma treatment
June 6, 2010 by admin · Leave a Comment
Molecular imaging is leading to more individualized and effective treatment for non-Hodgkins lymphoma by providing a map to guide the path of therapy
SALT LAKE CITYAccording to a study presented at SNM’s 57th Annual Meeting, molecular imaging can evaluate and optimize non-Hodgkin’s lymphoma therapy with Zevalin, a front-line radioimmunotherapy drug that uses a dose of radioactive material and mimics the body’s own immune response to target and kill cancer cells while sparing nearby healthy tissues.
Study identifies promising treatment for aggressive lymphoma
May 25, 2010 by admin · Leave a Comment
Contact: Karl Oestreich
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
CHICAGO — New research illustrates that some patients with transformed lymphoma showed “remarkable” response to lenalidomide, an oral drug with few side effects.
Treatment of Helicobacter pylori-negative gastric MALT lymphoma
May 6, 2010 by admin · Leave a Comment
Contact: Ye-Ru Wang
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Eradication of Helicobacter pylori (H. pylori) is a well-accepted initial therapy in cases of localized (stage ⅠE) low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma associated with H. pylori infection. However, there are no treatment guidelines for the management of H. pylori-negative low-grade gastric MALT lymphoma.
‘Junk DNA’ drives cancer growth
May 1, 2010 by admin · Leave a Comment
Contact: Paula Gould
p.a.gould@leeds.ac.uk
44-113-343-8059
University of Leeds
Researchers from the University of Leeds, UK, the Charité University Medical School and the Max Delbrück Centre for Molecular Medicine (MDC) in Berlin, Germany, have discovered a new driving force behind cancer growth.
